Accure Therapeutics Launches with Focus on Nervous System Disorders

Accure Therapeutics Launches with Focus on Nervous System Disorders
Accure Therapeutics announced its opening, supported by €7.6 million (about $8.1 million) in Series A funding. The Barcelona, Spain-based pharmaceutical company will focus on developing treatment candidates for central nervous system (CNS) disorders such as Parkinson’s disease. The funding round was led by Alta Life Sciences, and supported by the Centre for Technological and Industrial Development. For Parkinson’s, the company’s lead candidate ... read more
Source: Parkinson’s News TodayPublished on 2020-06-02By Mary Chapman